ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Eligible age
18+ yrs
Accepts
All genders
Locations
20 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Sponsor: Guardant Health, Inc.
You may qualify if…
- ✓ Age \> 18 years old AND
- ✓ Initial treatment is given with curative/radical intent AND
- ✓ Are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at the enrolling site AND
- ✓ Provided written informed consent to participate in the study AND
- ✓ Are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent AND
- ✓ Are willing to provide blood samples at enrollment and at subsequent clinical visits coinciding with standard of care follow-up, for up to 3 years as outlined in the study protocol and informed consent AND
- ✓ Have at least one Landmark blood sample collected. Landmark samples are collected 3-12 weeks after surgery, chemotherapy and/or radiation/chemoradiation as applicable based on the participant's planned treatment regimen
- ✓ Have a histologically confirmed Index Cancer that qualifies for inclusion, defined as:
You may not qualify if…
- ✕ History of allogeneic organ or tissue transplant
- ✕ Index cancer has predominantly neuroendocrine histology
- ✕ History of another primary cancer diagnosed within 3 years of enrollment, with the exception that in situ cancers, non-melanoma skin carcinomas, localized low- or intermediate risk prostate cancers (defined as cancers confined to the prostate with Gleason score of 7 or lower and prostate-specific antigen (PSA) of less than 20), and stage I papillary thyroid carcinoma, and participants with bilateral/multifocal tumors within the same organ (for example, bilateral breast cancer) are allowed if diagnosed within 3 years of enrollment
- ✕ Known distant metastasis at time of enrollment (with the exception of participants with limited/resectable stage IV cutaneous melanoma or RCC)
Where it's recruiting
Birmingham
Chandler
Hot Springs
La Jolla · Newport Beach · Redwood City · Sacramento
Aurora
Hollywood · Lakeland
New Orleans · Shreveport
Lewiston
Boston
Grand Rapids
Rochester
East Brunswick
Source: ClinicalTrials.gov · NCT05059444 · last updated 2026-09-14